These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 25144458)
1. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. Ronchi CL; Sbiera S; Volante M; Steinhauer S; Scott-Wild V; Altieri B; Kroiss M; Bala M; Papotti M; Deutschbein T; Terzolo M; Fassnacht M; Allolio B PLoS One; 2014; 9(8):e105855. PubMed ID: 25144458 [TBL] [Abstract][Full Text] [Related]
2. Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas. Nolé P; Duijndam B; Stenman A; Juhlin CC; Kozyra M; Larsson C; Ingelman-Sundberg M; Johansson I PLoS One; 2016; 11(9):e0162379. PubMed ID: 27598485 [TBL] [Abstract][Full Text] [Related]
3. [Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer]. Tkachuk AV; Beltsevich DG; Porubayeva EE; Urusova LS Probl Endokrinol (Mosk); 2023 Jan; 68(6):76-88. PubMed ID: 36689714 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359 [TBL] [Abstract][Full Text] [Related]
5. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196 [TBL] [Abstract][Full Text] [Related]
6. Survivin in adrenocortical tumors - pathophysiological implications and therapeutic potential. Sbiera S; Kroiss M; Thamm T; Beyer M; Majidi F; Kuehner D; Wobser M; Becker JC; Adam P; Ronchi C; Allolio B; Fassnacht M Horm Metab Res; 2013 Feb; 45(2):137-46. PubMed ID: 23143666 [TBL] [Abstract][Full Text] [Related]
7. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514 [TBL] [Abstract][Full Text] [Related]
8. Update in adrenocortical carcinoma. Fassnacht M; Kroiss M; Allolio B J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734 [TBL] [Abstract][Full Text] [Related]
9. New perspectives for mitotane treatment of adrenocortical carcinoma. Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008 [TBL] [Abstract][Full Text] [Related]
10. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm. Abdel-Aziz TE; Rajeev P; Sadler G; Weaver A; Mihai R World J Surg; 2015 May; 39(5):1268-73. PubMed ID: 25526921 [TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression. Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009 [TBL] [Abstract][Full Text] [Related]
12. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. Doghman M; Lalli E Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534 [TBL] [Abstract][Full Text] [Related]
13. Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Liang R; Weigand I; Lippert J; Kircher S; Altieri B; Steinhauer S; Hantel C; Rost S; Rosenwald A; Kroiss M; Fassnacht M; Sbiera S; Ronchi CL Front Endocrinol (Lausanne); 2020; 11():219. PubMed ID: 32373071 [TBL] [Abstract][Full Text] [Related]
14. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412 [TBL] [Abstract][Full Text] [Related]
15. Adjuvant mitotane in adrenocortical carcinoma. Machens A; Dralle H N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837 [No Abstract] [Full Text] [Related]
16. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187 [TBL] [Abstract][Full Text] [Related]
17. Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Altieri B; Sbiera S; Herterich S; De Francia S; Della Casa S; Calabrese A; Pontecorvi A; Quinkler M; Kienitz T; Mannelli M; Canu L; Angelousi A; Chortis V; Kroiss M; Terzolo M; Fassnacht M; Ronchi CL Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033200 [TBL] [Abstract][Full Text] [Related]
18. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884 [TBL] [Abstract][Full Text] [Related]
19. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma. Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888 [TBL] [Abstract][Full Text] [Related]